| Literature DB >> 23908493 |
Jessica M Fogel1, Lei Wang, Teresa L Parsons, San-San Ou, Estelle Piwowar-Manning, Ying Chen, Victor O Mudhune, Mina C Hosseinipour, Johnstone Kumwenda, James G Hakim, Suwat Chariyalertsak, Ravindre Panchia, Ian Sanne, Nagalingeswaran Kumarasamy, Beatriz Grinsztejn, Joseph Makhema, Jose Pilotto, Breno R Santos, Kenneth H Mayer, Marybeth McCauley, Theresa Gamble, Namandjé N Bumpus, Craig W Hendrix, Myron S Cohen, Susan H Eshleman.
Abstract
The HIV Prevention Trials Network 052 study enrolled serodiscordant couples. Index participants infected with human immunodeficiency virus reported no prior antiretroviral (ARV) treatment at enrollment. ARV drug testing was performed retrospectively using enrollment samples from a subset of index participants. ARV drugs were detected in 45 of 96 participants (46.9%) with an undetectable viral load, 2 of 48 (4.2%) with a low viral load, and 1 of 65 (1.5%) with a high viral load (P < .0001); they were also detected in follow-up samples from participants who were not receiving study-administered treatment. ARV drug testing may be useful in addition to self-report of ARV drug use in some clinical trial settings.Entities:
Keywords: Africa; HIV; HPTN 052; antiretroviral drug; clinical trial; self-report
Mesh：
Substances：
Year: 2013 PMID： 23908493 PMCID： PMC3805242 DOI： 10.1093/infdis/jit390
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226